-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical (600196.SH): Release of AR1001 phase III clinical trial data for the oral drug under development and has not exercised exclusive options

Zhitongcaijing·11/17/2026 00:57:02
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that in May 2026, the holding subsidiary Fosun Pharmaceutical Industry signed an “Exclusive Option Agreement” with AriBio. (This mainly includes) Fosun Pharmaceutical Industry was granted and enjoyed new licensing regions around the world (including core markets such as the United States, Europe, Japan, etc.) and licensing fields (that is, for the diagnosis, prevention and treatment of all types of Alzheimer's disease) licensed products (that is, using the AR1001 molecule as its active ingredient <whether or not the only active ingredient) > the exclusive right of choice of drug) rights.

On November 16, 2026, EST, the top-line data results of the global multi-center phase III clinical trial (POLARIS-AD study) of the oral drug AR1001 for the treatment of early-stage Alzheimer's disease were first announced in the form of an oral report at the 19th Alzheimer's Disease Clinical Trial Conference (CTAD 2026) held in Boston, USA. The clinical trial protocol is expected to be evaluated separately in the two main analysis groups. According to the oral report, data related to the phase III clinical trial showed that in the single-drug treatment population 1, the main endpoint of the clinical trial, CDR-SB (Clinical Dementia Assessment Scale - Total Score), achieved statistically significant results; in the overall population, the treatment group showed differences between groups compared to the placebo group, but did not achieve statistical significance.

As of the date of this announcement (i.e. November 17, 2026, same below), Fosun Pharmaceutical Industry has not exercised exclusive rights to choose the new global licensing areas mentioned above, and potential licenses have not yet been reached. Fosun Pharmaceutical Industry will further analyze and evaluate research data related to AR1001 (including but not limited to the phase III clinical trial top-line data described above) to decide whether to exercise the aforementioned right of choice.